Live feed
·
PRReleasevia Quantisnow
Oric Pharmaceuticals Inc. logo

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ByQuantisnow·Wall Street's wire, on your screen.
ORIC· Oric Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORIC (Oric Pharmaceuticals Inc.) and more on Quantisnow.